Abstract
Background:
Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA).
Method:
Prospective, observational study.
Results:
We found a reduction of the annualized relapse rate from 2.1 under IFN-beta or GA to 0.2 one year after switching to natalizumab. There were 94% fewer gadolinium enhancing lesions with natalizumab.
Conclusion:
Natalizumab reduced short term clinical and MRI activity in second line therapy and efficacy is comparable to first line therapy as demonstrated in the pivotal trials.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Brain / pathology
-
Disease Progression
-
Female
-
Gadolinium
-
Glatiramer Acetate
-
Humans
-
Immunologic Factors / therapeutic use
-
Interferon-beta / therapeutic use
-
Magnetic Resonance Imaging
-
Male
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
-
Multiple Sclerosis, Relapsing-Remitting / pathology
-
Natalizumab
-
Neuroprotective Agents / adverse effects
-
Neuroprotective Agents / therapeutic use*
-
Peptides / therapeutic use
-
Pilot Projects
-
Recurrence
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
Natalizumab
-
Neuroprotective Agents
-
Peptides
-
Glatiramer Acetate
-
Interferon-beta
-
Gadolinium